Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,498 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01514448 | Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib | completed | Phase 4 | 29 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 19, 2017 | clinicaltrials |
| NCT03038321 | Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects? | unknown | Phase 4 | 150 | Mansoura UniversityOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT02035345 | Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment | terminated | Phase 4 | 15 | Massachusetts General HospitalOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00172003 | Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis | completed | Phase 4 | 50 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
| NCT01402089 | Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients | completed | Phase 4 | 54 | Markus JoergerOTHER | 1 | Feb 2, 2016 | clinicaltrials |
| NCT00930345 | Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma(PREINSUT) | terminated | Phase 4 | 33 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 1, 2015 | clinicaltrials |
| NCT00352859 | Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib | terminated | Phase 4 | 2 | BayerINDUSTRY | 1 | Dec 30, 2014 | clinicaltrials |
| NCT02056587 | Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment | completed | Phase 4 | 37 | Kidney Cancer Research BureauOTHER | 1 | Feb 6, 2014 | clinicaltrials |
| NCT00706706 | Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma(MRCC RCC) | completed | Phase 4 | 105 | PfizerINDUSTRY | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00777504 | Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | unknown | Phase 4 | 30 | Radboud University Medical CenterOTHER | 1 | Sep 16, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Jul 19, 2017source: clinicaltrials